L10.81

Clinical Causes: The immune system produces antibodies that mistakenly attack skin and mucous membrane tissues. Presence of an associated underlying neoplasm, most commonly hematologic cancers such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, or Castleman’s disease. Genetic predispositions that may influence immune system behavior, although specific genetic factors are not well established.

Key Symptoms: Painful erosions and blisters on the skin, especially around the trunk, face, and extremities. Severe ongoing erosions and blisters affecting mucous membranes, including the mouth, eyes, and respiratory tract. Difficulty swallowing or speaking due to oral and oropharyngeal involvement. Conjunctivitis or eye discomfort caused by mucous membrane exposure. Fever and general malaise may be present, particularly if an underlying malignancy is active. Skin lesions that may appear as erythematous or blistered patches that can rapidly progress.

Diagnosis Path: Diagnosing paraneoplastic pemphigus involves a combination of clinical evaluation, laboratory tests, and histopathology. Key diagnostic approaches include: - Physical examination to identify characteristic skin and mucous membrane lesions. - Skin or mucous membrane biopsy for histopathological analysis, revealing acantholysis and interface dermatitis. - Direct immunofluorescence testing to detect autoantibodies deposited in the skin. - Blood tests to measure circulating autoantibodies targeting plakin family proteins and other skin components. - Screening for underlying neoplasms using imaging studies such as CT scans, PET scans, or biopsies of suspected tumors. The diagnosis is often confirmed when characteristic clinical features are present alongside laboratory evidence of autoantibodies and an identified neoplasm.

Treatment Protocols: Management of paraneoplastic pemphigus typically involves addressing both the skin condition and the associated malignancy. Treatment strategies may include: - Immunosuppressive therapies, such as corticosteroids, to reduce immune system activity and decrease blister formation. - Adjunct immunomodulatory drugs like rituximab, cyclophosphamide, or intravenous immunoglobulin (IVIG), aimed at controlling autoantibody production. - Topical therapies and protective dressings to manage skin erosions and prevent infection. - Antibiotics or antifungal agents if secondary infections occur. - Treating the underlying tumor with appropriate oncologic interventions like surgery, chemotherapy, or radiation therapy can sometimes lead to improvement of skin symptoms. - Supportive care including pain management, nutritional support, and eye care if mucous membranes are involved. Due to the complexity of this condition, comprehensive multidisciplinary care is often required for optimal management.